

## References

### I-220

1. Preferred Drug List (PDL) Prior Authorization Criteria. North Dakota Department of Human Services. Medical Services Division. <http://www.hidesigns.com/ndmedicaid/pdl/2021.html>
2. Tepezza™ (teprotumumab-trbw), for injection, for intravenous use [package insert]. Horizon Therapeutics, Inc. Lake Forest, IL. 01/2020.
3. Clinical Pharmacology™ 2020. Tampa FL: Gold Standard, Inc. teprotumumab-trbw.
4. Micromedex DrugDex Compendium®. 2020. Teprotumumab-trbw.
5. Hayes, Inc. Hayes Emerging Technology Report. Tepezza (Teprotumumab-trbw) for Thyroid Eye Disease. Lansdale, PA: Hayes, Inc.; January 2020.
6. Smith T, Kahaly G, Ezra D, et al. Teprotumumab for Thyroid-Associated Ophthalmopathy. *N Engl J Med.* 2017;376:1748-1761.
7. Douglas R, Kahaly G, Patel A, et al. Teprotumumab for the Treatment of Active Thyroid Eye Disease. *N Engl J Med.* 2020;382:341-352.
8. Mitchell A, Goss L, Mathiopoulou L, et al. Diagnosis of Graves' Orbitopathy (DiaGO): Results of a Pilot Study to Assess the Utility of an Office Tool for Practicing Endocrinologists. *J Clin Endocrinol Metab.* 2015;100(3):E458-E462.